Lenalidomide (CC-5013), a derivative of Thalidomide, acts as molecular glue for PROTAC design, Lenalidomide is a ligand of ubiquitin E3 ligase cereblon (CRBN), and causes selective ubiquitination and degradation of IKZF1 and IKZF3, by the CRBN-CRL4 ubiquitin ligase.
Lenalidomide (CC-5013) specifically inhibits growth of mature B-cell lymphomas, including multiple myeloma, and induces IL-2 release from T cells.
Lenalidomide (CC-5013) inhibits production of pro inflammatory cytokines TNF-α, IL-1, IL-6, IL-12 and elevates the production of anti-inflammatory cytokine IL-10 from human PBMCs.
Lenalidomide (CC-5013) downregulates the production of IL-6 directly and also by inhibiting multiple myeloma (MM) cells and bone marrow stromal cells (BMSC) interaction.
Orally administered lenalidomide (250 mg/kg per day) reduces vascularization and total microvascular length in a rat mesenteric window assay.